Top

Published in:

01-07-2019 | Affective Disorder | Review

Subclinical inflammation and depressive symptoms in patients with type 1 and type 2 diabetes

Authors: Christian Herder, Norbert Hermanns

Published in: Seminars in Immunopathology | Issue 4/2019

Abstract

Depression is a frequent comorbidity of type 1 diabetes (T1D) and type 2 diabetes (T2D). Depression and diabetes are linked by a bidirectional relationship, but the underlying mechanisms are still incompletely understood. Experimental, observational and intervention studies showed that inflammatory processes contribute to the development of depression in animal models and humans. Given the high risk of morbidity and mortality in patients with the double burden of diabetes and depression, this review provides an overview of epidemiological studies that addressed the relationship between biomarkers of inflammation and depressive symptoms or depression in diabetes patients. In patients with T1D, there is some evidence that higher levels of high-sensitivity C-reactive protein (hsCRP), IL-6, IL-1 receptor antagonist (IL-1RA) and sICAM-1 may be related to depressive symptoms or (for hsCRP) lower treatment response. For T2D, hsCRP, IL-1RA, CCL2 and adiponectin or its isoforms were associated with depressive symptoms in at least two studies, whereas positive associations of IL-1β, IL-6 and IL-18 with depressive symptoms or depression were reported from single cohorts. However, the number of studies is too low for any meaningful meta-analysis. Prospective life course studies including both patients with T1D and T2D, a comprehensive assessment of systemic inflammation and repeated assessment of depressive symptoms should represent a future research priority to clarify to what extent subclinical inflammation affects the risk of depression in patients with diabetes. A better understanding of the role of inflammatory processes may help to identify subtypes of depression with partly different pathogenesis, which could have consequences with respect to therapeutic options including immunomodulation.

Kupfer DJ, Frank E, Phillips ML (2012) Major depressive disorder: new clinical, neurobiological, and treatment perspectives. Lancet 379:1045–1055. https://doi.org/10.1016/S0140-6736(11)60602-8 CrossRefPubMed

Pouwer F, Kupper N, Adriaanse MC (2010) Does emotional stress cause type 2 diabetes mellitus? A review from the European depression in diabetes (EDID) research consortium. Discov Med 9:112–118PubMed

Pouwer F (2017) Depression: a common and burdensome complication of diabetes that warrants the continued attention of clinicians, researchers and healthcare policy makers. Diabetologia 60:30–34. https://doi.org/10.1007/s00125-016-4154-6 CrossRefPubMed

Golden SH, Lazo M, Carnethon M, Bertoni AG, Schreiner PJ, Diez Roux AV, Lee HB, Lyketsos C (2008) Examining a bidirectional association between depressive symptoms and diabetes. JAMA 299:2751–2759. https://doi.org/10.1001/jama.299.23.2751 CrossRefPubMedPubMedCentral

Pan A, Lucas M, Sun Q, van Dam RM, Franco OH, Manson JE, Willett WC, Ascherio A, Hu FB (2010) Bidirectional association between depression and type 2 diabetes mellitus in women. Arch Intern Med 170:1884–1891. https://doi.org/10.1001/archinternmed.2010.356 CrossRefPubMedPubMedCentral

Stuart MJ, Baune BT (2012) Depression and type 2 diabetes: inflammatory mechanisms of a psychoneuroendocrine co-morbidity. Neurosci Biobehav Rev 36:658–676. https://doi.org/10.1016/j.neubiorev.2011.10.001 CrossRefPubMed

Tabák AG, Akbaraly TN, Batty GD, Kivimäki M (2014) Depression and type 2 diabetes: a causal association? Lancet Diabetes Endocrinol 2:236–245. https://doi.org/10.1016/S2213-8587(13)70139-6 CrossRefPubMed

Furtado M, Katzman MA (2015) Examining the role of neuroinflammation in major depression. Psychiatry Res 229:27–36. https://doi.org/10.1016/j.psychres.2015.06.009 CrossRefPubMed

Korczak DJ, Pereira S, Koulajian K, Matejcek A, Giacca A (2011) Type 1 diabetes mellitus and major depressive disorder: evidence for a biological link. Diabetologia 54:2483–2493. https://doi.org/10.1007/s00125-011-2240-3 CrossRefPubMed

10.

Miller AH, Raison CL (2016) The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol 16:22–34. https://doi.org/10.1038/nri.2015.5 CrossRefPubMedPubMedCentral

11.

Herder C, Dalmas E, Böni-Schnetzler M, Donath MY (2015) The IL-1 pathway in type 2 diabetes and cardiovascular complications. Trends Endocrinol Metab 26:551–563. https://doi.org/10.1016/j.tem.2015.08.001 CrossRefPubMed

12.

Bäck M, Hansson GK (2015) Anti-inflammatory therapies for atherosclerosis. Nat Rev Cardiol 12:199–211. https://doi.org/10.1038/nrcardio.2015.5 CrossRefPubMed

13.

Ridker PM, Everett BM, Thuren T, Mac-Fadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ, CANTOS Trial Group (2017) Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 377:1119–1131. https://doi.org/10.1056/NEJMoa1707914 CrossRefPubMed

14.

Herder C, Kannenberg JM, Huth C, Carstensen-Kirberg M, Rathmann W, Koenig W, Heier M, Püttgen S, Thorand B, Peters A, Roden M, Meisinger C, Ziegler D (2017) Proinflammatory cytokines predict the incidence and progression of distal sensorimotor polyneuropathy: KORA F4/FF4 study. Diabetes Care 40:569–576. https://doi.org/10.2337/dc16-2259 CrossRefPubMed

15.

Herder C, Kannenberg JM, Carstensen-Kirberg M, Strom A, Bönhof GJ, Rathmann W, Huth C, Koenig W, Heier M, Krumsiek J, Peters A, Meisinger C, Roden M, Thorand B, Ziegler D (2018) A systemic inflammatory signature reflecting crosstalk between innate and adaptive immunity is associated with incident polyneuropathy: KORA F4/FF4 study. Diabetes 67:2434–2442. https://doi.org/10.2337/db18-0060 CrossRefPubMed

16.

Donate-Correa J, Martín-Núñez E, Muros-de-Fuentes M, Mora-Fernández C, Navarro-González JF (2015) Inflammatory cytokines in diabetic nephropathy. J Diabetes Res 2015:948417. https://doi.org/10.1155/2015/948417 CrossRefPubMedPubMedCentral

17.

Zoccali C, Vanholder R, Massy ZA, Ortiz A, Sarafidis P, Dekker FW, Fliser D, Fouque D, Heine GH, Jager KJ, Kanbay M, Mallamaci F, Parati G, Rossignol P, Wiecek A, London G, European Renal and Cardiovascular Medicine (EURECA-m) Working Group of the European Renal Association – European Dialysis Transplantation Association (ERA-EDTA) (2017) The systemic nature of CKD. Nat Rev Nephrol 13:344–358. https://doi.org/10.1038/nrneph.2017.52 CrossRefPubMed

18.

Colhoun HM, Marcovecchio ML (2018) Biomarkers of diabetic kidney disease. Diabetologia 61:996–1011. https://doi.org/10.1007/s00125-018-4567-5 CrossRefPubMedPubMedCentral

19.

Simó-Servat O, Simó R, Hernández C (2016) Circulating biomarkers of diabetic retinopathy: an overview based on physiopathology. J Diabetes Res 2016:5263798. https://doi.org/10.1155/2016/5263798 CrossRefPubMedPubMedCentral

20.

Vujosevic S, Simó R (2017) Local and systemic inflammatory biomarkers of diabetic retinopathy: an integrative approach. Invest Ophthalmol Vis Sci 58:BIO68–BIO75. https://doi.org/10.1167/iovs.17-21769 CrossRefPubMed

21.

Rübsam A, Parikh S, Fort PE (2018) Role of inflammation in diabetic retinopathy. Int J Mol Sci 19:942. https://doi.org/10.3390/ijms19040942 CrossRefPubMedCentral

22.

Howren MB, Lamkin DM, Suls J (2009) Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med 71:171–186. https://doi.org/10.1097/PSY.0b013e3181907c1b CrossRefPubMed

23.

Hiles SA, Baker AL, de Malmanche T, Attia J (2012) A meta-analysis of differences in IL-6 and IL-10 between people with and without depression: exploring the causes of heterogeneity. Brain Behav Immun 26:1180–1188. https://doi.org/10.1016/j.bbi.2012.06.001 CrossRefPubMed

24.

Haapakoski R, Mathieu J, Ebmeier KP, Alenius H, Kivimäki M (2015) Cumulative meta-analysis of interleukins 6 and 1β, tumour necrosis factor α and C-reactive protein in patients with major depressive disorder. Brain Behav Immun 49:206–215. https://doi.org/10.1016/j.bbi.2015.06.001 CrossRefPubMedPubMedCentral

25.

Smith KJ, Au B, Ollis L, Schmitz N (2018) The association between C-reactive protein, interleukin-6 and depression among older adults in the community: a systematic review and meta-analysis. Exp Gerontol 102:109–132. https://doi.org/10.1016/j.exger.2017.12.005 CrossRefPubMed

26.

Valkanova V, Ebmeier KP, Allan CL (2013) CRP, IL-6 and depression: a systematic review and meta-analysis of longitudinal studies. J Affect Disord 150:736–744. https://doi.org/10.1016/j.jad.2013.06.004 CrossRefPubMed

27.

Anderson RJ, Freedland KE, Clouse RE, Lustman PJ (2001) The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care 24:1069–1078CrossRefPubMed

28.

Kruse J, Schmitz N, Thefeld W (2003) On the association between diabetes and mental disorders in a community sample: results from the German National Health Interview and examination survey. Diabetes Care 26:1841–1846CrossRefPubMed

29.

Roy T, Lloyd CE (2012) Epidemiology of depression and diabetes: a systematic review. J Affect Disord 142(Suppl):S8–S21. https://doi.org/10.1016/S0165-0327(12)70004-6 CrossRefPubMed

30.

Moussavi S, Chatterji S, Verdes E, Tandon A, Patel V, Ustun B (2007) Depression, chronic diseases, and decrements in health: results from the world health surveys. Lancet 370:851–858CrossRefPubMed

31.

Egede LE (2007) Major depression in individuals with chronic medical disorders: prevalence, correlates and association with health resource utilization, lost productivity and functional disability. Gen Hosp Psychiatry 29:409–416CrossRefPubMed

32.

Surwit R, Schneider M, Feinglos M (1992) Stress and diabetes mellitus. Diabetes Care 15:1413–1420CrossRefPubMed

33.

Kulzer B (2005) Depression—an important obstruction to the treatment of diabetes; article in German. MMW Fortschr Med 147:37–40PubMed

34.

Snoek FJ, Bremmer MA, Hermanns N (2015) Constructs of depression and distress in diabetes: time for an appraisal. Lancet Diabetes Endocrinol 3:450–460. https://doi.org/10.1016/S2213-8587(15)00135-7 CrossRefPubMed

35.

Nouwen A, Winkley K, Twisk J, Lloyd CE, Peyrot M, Ismail K, Pouwer F, European Depression in Diabetes (EDID) Research Consortium (2010) Type 2 diabetes mellitus as a risk factor for the onset of depression: a systematic review and meta-analysis. Diabetologia 53:2480–2486. https://doi.org/10.1007/s00125-010-1874-x CrossRefPubMedPubMedCentral

36.

Willis T (1675) Pharmaceutice rationalis sive diabtriba de medicamentorum operantionibus in humano corpore, Oxford

37.

Knol MJ, Twisk JW, Beekman AT, Heine RJ, Snoek FJ, Pouwer F (2006) Depression as a risk factor for the onset of type 2 diabetes mellitus. A meta-analysis. Diabetologia 49:837–345CrossRefPubMed

38.

Rotella F, Mannucci E (2013) Diabetes mellitus as a risk factor for depression. A meta-analysis of longitudinal studies. Diabetes Res Clin Pract 99:98–104. https://doi.org/10.1016/j.diabres.2012.11.022 CrossRefPubMed

39.

Kan C, Silva N, Golden SH, Rajala U, Timonen M, Stahl D, Ismail K (2013) A systematic review and meta-analysis of the association between depression and insulin resistance. Diabetes Care 36:480–489. https://doi.org/10.2337/dc12-1442 Erratum in: Diabetes Care 2013;36:1429CrossRefPubMedPubMedCentral

40.

Goldney RD, Phillips PJ, Fisher LJ, Wilson DH (2004) Diabetes, depression, and quality of life: a population study. Diabetes Care 27:1066–1070CrossRefPubMed

41.

Gonzalez JS, Peyrot M, McCarl LA, Collins EM, Serpa L, Mimiaga MJ, Safren SA (2008) Depression and diabetes treatment nonadherence: a meta-analysis. Diabetes Care 31:2398–2403. https://doi.org/10.2337/dc08-1341 CrossRefPubMedPubMedCentral

42.

Ciechanowski PS, Katon WJ, Russo JE, Hirsch IB (2003) The relationship of depressive symptoms to symptom reporting, self-care and glucose control in diabetes. Gen Hosp Psychiatry 25:246–252CrossRefPubMed

43.

Lustman PJ, Anderson RJ, Freedland KE, de Groot M, Carney RM, Clouse RE (2000) Depression and poor glycemic control: a meta-analytic review of the literature. Diabetes Care 23:934–942CrossRefPubMed

44.

Schmitt A, Gahr A, Hermanns N, Kulzer B, Huber J, Haak T (2013) The diabetes self-management questionnaire (DSMQ): development and evaluation of an instrument to assess diabetes self-care activities associated with glycaemic control. Health Qual Life Outcomes 11:138. https://doi.org/10.1186/1477-7525-11-138 CrossRefPubMedPubMedCentral

45.

Black SA, Markides KS, Ray LA (2003) Depression predicts increased incidence of adverse health outcomes in older Mexican Americans with type 2 diabetes. Diabetes Care 26:2822–2828CrossRefPubMed

46.

Schmitz N, Gariépy G, Smith KJ, Clyde M, Malla A, Boyer R, Strychar I, Lesage A, Wang J (2014) Recurrent subthreshold depression in type 2 diabetes: an important risk factor for poor health outcomes. Diabetes Care 37:970–978. https://doi.org/10.2337/dc13-1832 CrossRefPubMed

47.

van Dooren FE, Schram MT, Schalkwijk CG, Stehouwer CD, Henry RM, Dagnelie PC, Schaper NC, van der Kallen CJ, Koster A, Sep SJ, Denollet J, Verhey FR, Pouwer F (2016) Associations of low grade inflammation and endothelial dysfunction with depression—the Maastricht study. Brain Behav Immun 56:390–396. https://doi.org/10.1016/j.bbi.2016.03.004 CrossRefPubMed

48.

Zhang X, Norris SL, Gregg EW, Cheng YJ, Beckles G, Kahn HS (2005) Depressive symptoms and mortality among persons with and without diabetes. Am J Epidemiol 161:652–660CrossRefPubMed

49.

Egede LE (2005) Effect of depression on self-management behaviors and health outcomes in adults with type 2 diabetes. Curr Diabetes Rev 1:235–243CrossRefPubMed

50.

Katon W, Fan MY, Unützer J, Taylor J, Pincus H, Schoenbaum M (2008) Depression and diabetes: a potentially lethal combination. J Gen Intern Med 23:1571–1575. https://doi.org/10.1007/s11606-008-0731-9 CrossRefPubMedPubMedCentral

51.

Holt RI, de Groot M, Lucki I, Hunter CM, Sartorius N, Golden SH (2014) NIDDK international conference report on diabetes and depression: current understanding and future directions. Diabetes Care 37:2067–2077. https://doi.org/10.2337/dc13-2134 CrossRefPubMedPubMedCentral

52.

Moulton CD, Pickup JC, Ismail K (2015) The link between depression and diabetes: the search for shared mechanisms. Lancet Diabetes Endocrinol 3:461–471. https://doi.org/10.1016/S2213-8587(15)00134-5 CrossRefPubMed

53.

Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW (2008) From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 9:46–56CrossRefPubMedPubMedCentral

54.

Ho N, Sommers MS, Lucki I (2013) Effects of diabetes on hippocampal neurogenesis: links to cognition and depression. Neurosci Biobehav Rev 37:1346–1362. https://doi.org/10.1016/j.neubiorev.2013.03.010 CrossRefPubMedPubMedCentral

55.

Han QQ, Yu J (2014) Inflammation: a mechanism of depression? Neurosci Bull 30:515–523. https://doi.org/10.1007/s12264-013-1439-3 CrossRefPubMedPubMedCentral

56.

Berk M, Williams LJ, Jacka FN, O'Neil A, Pasco JA, Moylan S, Allen NB, Stuart AL, Hayley AC, Byrne ML, Maes M (2013) So depression is an inflammatory disease, but where does the inflammation come from? BMC Med 11:200. https://doi.org/10.1186/1741-7015-11-200 CrossRefPubMedPubMedCentral

57.

Kuhlman KR, Robles TF, Dooley LN, Boyle CC, Haydon MD, Bower JE (2018) Within-subject associations between inflammation and features of depression: using the flu vaccine as a mild inflammatory stimulus. Brain Behav Immun 69:540–547. https://doi.org/10.1016/j.bbi.2018.02.001 CrossRefPubMedPubMedCentral

58.

Kaufmann FN, Costa AP, Ghisleni G, Diaz AP, Rodrigues ALS, Peluffo H, Kaster MP (2017) NLRP3 inflammasome-driven pathways in depression: clinical and preclinical findings. Brain Behav Immun 64:367–383. https://doi.org/10.1016/j.bbi.2017.03.002 CrossRefPubMed

59.

Franklin TC, Xu C, Duman RS (2018) Depression and sterile inflammation: essential role of danger associated molecular patterns. Brain Behav Immun 72:2–13. https://doi.org/10.1016/j.bbi.2017.10.025 CrossRefPubMed

60.

Stein DJ, Naudé PJ, Berk M (2018) Stress, depression, and inflammation: molecular and microglial mechanisms. Biol Psychiatry 83:5–6. https://doi.org/10.1016/j.biopsych.2017.10.025 CrossRefPubMed

61.

Gandal MJ, Haney JR, Parikshak NN, Leppa V, Ramaswami G, Hartl C, Schork AJ, Appadurai V, Buil A, Werge TM, Liu C, White KP, CommonMind Consortium; PsychENCODE Consortium; iPSYCH-BROAD Working Group, Horvath S, Geschwind DH (2018) Shared molecular neuropathology across major psychiatric disorders parallels polygenic overlap. Science 359:693–697. https://doi.org/10.1126/science.aad6469 CrossRefPubMedPubMedCentral

62.

Felger JC, Haroon E, Patel TA, Goldsmith DR, Wommack EC, Woolwine BJ, Le NA, Feinberg R, Tansey MG, Miller AH (2018) What does plasma CRP tell us about peripheral and central inflammation in depression? Mol Psychiatry 2018. https://doi.org/10.1038/s41380-018-0096-3

63.

Liu Y, Ho RC, Mak A (2012) Interleukin (IL)-6, tumour necrosis factor alpha (TNF-α) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression. J Affect Disord 139:230–239. https://doi.org/10.1016/j.jad.2011.08.003 CrossRefPubMed

64.

Milaneschi Y, Corsi AM, Penninx BW, Bandinelli S, Guralnik JM, Ferrucci L (2009) Interleukin-1 receptor antagonist and incident depressive symptoms over 6 years in older persons: the InCHIANTI study. Biol Psychiatry 65:973–978. https://doi.org/10.1016/j.biopsych.2008.11.011 CrossRefPubMed

65.

Eyre HA, Air T, Pradhan A, Johnston J, Lavretsky H, Stuart MJ, Baune BT (2016) A meta-analysis of chemokines in major depression. Prog Neuro-Psychopharmacol Biol Psychiatry 68:1–8. https://doi.org/10.1016/j.pnpbp.2016.02.006 CrossRef

66.

Köhler CA, Freitas TH, Maes M, de Andrade NQ, Liu CS, Fernandes BS, Stubbs B, Solmi M, Veronese N, Herrmann N, Raison CL, Miller BJ, Lanctôt KL, Carvalho AF (2017) Peripheral cytokine and chemokine alterations in depression: a meta-analysis of 82 studies. Acta Psychiatr Scand 135:373–387. https://doi.org/10.1111/acps.12698 CrossRefPubMed

67.

Leighton SP, Nerurkar L, Krishnadas R, Johnman C, Graham GJ, Cavanagh J (2018) Chemokines in depression in health and in inflammatory illness: a systematic review and meta-analysis. Mol Psychiatry 23:48–58. https://doi.org/10.1038/mp.2017.205 CrossRefPubMed

68.

Horn SR, Long MM, Nelson BW, Allen NB, Fisher PA, Byrne ML (2018) Replication and reproducibility issues in the relationship between C-reactive protein and depression: a systematic review and focused meta-analysis. Brain Behav Immun 73:85–114. https://doi.org/10.1016/j.bbi.2018.06.016 CrossRefPubMedPubMedCentral

69.

Jokela M, Virtanen M, Batty GD, Kivimäki M (2016) Inflammation and specific symptoms of depression. JAMA Psychiatry 73:87–88. https://doi.org/10.1001/jamapsychiatry.2015.1977 CrossRefPubMed

70.

White J, Kivimäki M, Jokela M, Batty GD (2017) Association of inflammation with specific symptoms of depression in a general population of older people: the English longitudinal study of ageing. Brain Behav Immun 61:27–30. https://doi.org/10.1016/j.bbi.2016.08.012 CrossRefPubMed

71.

Hannestad J, DellaGioia N, Bloch M (2011) The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology 36:2452–2459. https://doi.org/10.1038/npp.2011.132 CrossRefPubMedPubMedCentral

72.

Hiles SA, Baker AL, de Malmanche T, Attia J (2012) Interleukin-6, C-reactive protein and interleukin-10 after antidepressant treatment in people with depression: a meta-analysis. Psychol Med 42:2015–2026. https://doi.org/10.1017/S0033291712000128 CrossRefPubMed

73.

Baumeister D, Ciufolini S, Mondelli V (2016) Effects of psychotropic drugs on inflammation: consequence or mediator of therapeutic effects in psychiatric treatment? Psychopharmacology 233:1575–1589. https://doi.org/10.1007/s00213-015-4044-5 CrossRefPubMed

74.

Strawbridge R, Arnone D, Danese A, Papadopoulos A, Herane Vives A, Cleare AJ (2015) Inflammation and clinical response to treatment in depression: a meta-analysis. Eur Neuropsychopharmacol 25:1532–1543. https://doi.org/10.1016/j.euroneuro.2015.06.007 CrossRefPubMed

75.

Haroon E, Daguanno AW, Woolwine BJ, Goldsmith DR, Baer WM, Wommack EC, Felger JC, Miller AH (2018) Antidepressant treatment resistance is associated with increased inflammatory markers in patients with major depressive disorder. Psychoneuroendocrinology 95:43–49. https://doi.org/10.1016/j.psyneuen.2018.05.026 CrossRefPubMedPubMedCentral

76.

Hood KK, Lawrence JM, Anderson A, Bell R, Dabelea D, Daniels S, Rodriguez B, Dolan LM, SEARCH for Diabetes in Youth Study Group (2012) Metabolic and inflammatory links to depression in youth with diabetes. Diabetes Care 35:2443–2446. https://doi.org/10.2337/dc11-2329 CrossRefPubMedPubMedCentral

77.

Zahn D, Herpertz S, Albus C, Hermanns N, Hiemke C, Hiller W, Kronfeld K, Kruse J, Kulzer B, Müller MJ, Ruckes C, Petrak F (2016) hs-CRP predicts improvement in depression in patients with type 1 diabetes and major depression undergoing depression treatment: results from the diabetes and depression (DAD) study. Diabetes Care 39:e171–e173. https://doi.org/10.2337/dc16-0710 CrossRefPubMed

78.

Herder C, Fürstos JF, Nowotny B, Begun A, Strassburger K, Müssig K, Szendroedi J, Icks A, Roden M, GDS group (2017) Associations between inflammation-related biomarkers and depressive symptoms in individuals with recently diagnosed type 1 and type 2 diabetes. Brain Behav Immun 61:137–145. https://doi.org/10.1016/j.bbi.2016.12.025 CrossRefPubMed

79.

Herder C, Schmitt A, Budden F, Reimer A, Kulzer B, Roden M, Haak T, Hermanns N (2018) Association between pro- and anti-inflammatory cytokines and depressive symptoms in patients with diabetes—potential differences by diabetes type and depression scores. Transl Psychiatry 7:1. https://doi.org/10.1038/s41398-017-0009-2 CrossRefPubMedPubMedCentral

80.

Herder C, Schmitt A, Budden F, Reimer A, Kulzer B, Roden M, Haak T, Hermanns N (2018) Longitudinal associations between biomarkers of inflammation and changes in depressive symptoms in patients with type 1 and type 2 diabetes. Psychoneuroendocrinology 91:216–225. https://doi.org/10.1016/j.psyneuen.2018.02.032 CrossRefPubMed

81.

Doyle TA, de Groot M, Harris T, Schwartz F, Strotmeyer ES, Johnson KC, Kanaya A (2013) Diabetes, depressive symptoms, and inflammation in older adults: results from the health, aging, and body composition study. J Psychosom Res 75:419–424. https://doi.org/10.1016/j.jpsychores.2013.08.006 CrossRefPubMed

82.

Hayashino Y, Mashitani T, Tsujii S, Ishii H, Diabetes Distress and Care Registry at Tenri Study Group (2014) Elevated levels of hs-CRP are associated with high prevalence of depression in Japanese patients with type 2 diabetes: the diabetes distress and care registry at Tenri (DDCRT 6). Diabetes Care 37:2459–2465. https://doi.org/10.2337/dc13-2312 CrossRefPubMed

83.

Laake JP, Stahl D, Amiel SA, Petrak F, Sherwood RA, Pickup JC, Ismail K (2014) The association between depressive symptoms and systemic inflammation in people with type 2 diabetes: findings from the South London diabetes study. Diabetes Care 37:2186–2192. https://doi.org/10.2337/dc13-2522 CrossRefPubMed

84.

van Dooren FE, Nefs G, Schram MT, Verhey FR, Denollet J, Pouwer F (2013) Depression and risk of mortality in people with diabetes mellitus: a systematic review and meta-analysis. PLoS One 8:e57058. https://doi.org/10.1371/journal.pone.0057058 CrossRefPubMedPubMedCentral

85.

Herder C, Brunner EJ, Rathmann W, Strassburger K, Tabák AG, Schloot NC, Witte DR (2009) Elevated levels of the anti-inflammatory interleukin-1 receptor antagonist precede the onset of type 2 diabetes: the Whitehall II study. Diabetes Care 32:421–423. https://doi.org/10.2337/dc08-1161 CrossRefPubMedPubMedCentral

86.

Herder C, de Las Heras Gala T, Carstensen-Kirberg M, Huth C, Zierer A, Wahl S, Sudduth-Klinger J, Kuulasmaa K, Peretz D, Ligthart S, Bongaerts BWC, Dehghan A, Ikram MA, Jula A, Kee F, Pietilä A, Saarela O, Zeller T, Blankenberg S, Meisinger C, Peters A, Roden M, Salomaa V, Koenig W, Thorand B (2017) Circulating levels of interleukin 1-receptor antagonist and risk of cardiovascular disease: meta-analysis of six population-based cohorts. Arterioscler Thromb Vasc Biol 37:1222–1227. https://doi.org/10.1161/ATVBAHA.117.309307 CrossRefPubMed

87.

Schamarek I, Herder C, Nowotny B, Carstensen-Kirberg M, Straßburger K, Nowotny P, Strom A, Püttgen S, Müssig K, Szendroedi J, Roden M, Ziegler D, German Diabetes Study Group (2016) Adiponectin, markers of subclinical inflammation and nerve conduction in individuals with recently diagnosed type 1 and type 2 diabetes. Eur J Endocrinol 174:433–443. https://doi.org/10.1530/EJE-15-1010 CrossRefPubMed

88.

Herder C, Schamarek I, Nowotny B, Carstensen-Kirberg M, Straßburger K, Nowotny P, Kannenberg JM, Strom A, Püttgen S, Müssig K, Szendroedi J, Roden M, Ziegler D, German Diabetes Study Group (2017) Inflammatory markers are associated with cardiac autonomic dysfunction in recent-onset type 2 diabetes. Heart 103:63–70. https://doi.org/10.1136/heartjnl-2015-309181 CrossRefPubMed

89.

Bönhof GJ, Herder C, Strom A, Papanas N, Roden M, Ziegler D (2018, 2018) Emerging biomarkers, tools, and treatments for diabetic polyneuropathy. Endocr Rev 40:153–192. https://doi.org/10.1210/er.2018-00107

90.

Schloot NC, Pham MN, Hawa MI, Pozzilli P, Scherbaum WA, Schott M, Kolb H, Hunter S, Schernthaner G, Thivolet C, Seissler J, Leslie RD, Action LADA Group (2016) Inverse relationship between organ-specific autoantibodies and systemic immune mediators in type 1 diabetes and type 2 diabetes: Action LADA 11. Diabetes Care 39:1932–1939. https://doi.org/10.2337/dc16-0293 CrossRefPubMed

91.

Leslie RD, Palmer J, Schloot NC, Lernmark A (2016) Diabetes at the crossroads: relevance of disease classification to pathophysiology and treatment. Diabetologia 59:13–20. https://doi.org/10.1007/s00125-015-3789-z CrossRefPubMed

92.

Shariq AS, Brietzke E, Rosenblat JD, Barendra V, Pan Z, McIntyre RS (2018) Targeting cytokines in reduction of depressive symptoms: a comprehensive review. Prog Neuro-Psychopharmacol Biol Psychiatry 83:86–91. https://doi.org/10.1016/j.pnpbp.2018.01.003 CrossRef

93.

Fourrier C, Sampson E, Mills NT, Baune BT (2018) Anti-inflammatory treatment of depression: study protocol for a randomised controlled trial of vortioxetine augmented with celecoxib or placebo. Trials 19:447. https://doi.org/10.1186/s13063-018-2829-7 CrossRefPubMedPubMedCentral

94.

Kolb H, Mandrup-Poulsen T (2010) The global diabetes epidemic as a consequence of lifestyle-induced low-grade inflammation. Diabetologia 53:10–20. https://doi.org/10.1007/s00125-009-1573-7 CrossRefPubMed

95.

go back to reference Wray NR, Ripke S, Mattheisen M, Trzaskowski M, Byrne EM, Abdellaoui A, Adams MJ, Agerbo E, Air TM, Andlauer TMF, Bacanu SA, Bækvad-Hansen M, Beekman AFT, Bigdeli TB, Binder EB, Blackwood DRH, Bryois J, Buttenschøn HN, Bybjerg-Grauholm J, Cai N, Castelao E, Christensen JH, Clarke TK, Coleman JIR, Colodro-Conde L, Couvy-Duchesne B, Craddock N, Crawford GE, Crowley CA, Dashti HS, Davies G, Deary IJ, Degenhardt F, Derks EM, Direk N, Dolan CV, Dunn EC, Eley TC, Eriksson N, Escott-Price V, Kiadeh FHF, Finucane HK, Forstner AJ, Frank J, Gaspar HA, Gill M, Giusti-Rodríguez P, Goes FS, Gordon SD, Grove J, Hall LS, Hannon E, Hansen CS, Hansen TF, Herms S, Hickie IB, Hoffmann P, Homuth G, Horn C, Hottenga JJ, Hougaard DM, Hu M, Hyde CL, Ising M, Jansen R, Jin F, Jorgenson E, Knowles JA, Kohane IS, Kraft J, Kretzschmar WW, Krogh J, Kutalik Z, Lane JM, Li Y, Li Y, Lind PA, Liu X, Lu L, MacIntyre DJ, MacKinnon DF, Maier RM, Maier W, Marchini J, Mbarek H, McGrath P, McGuffin P, Medland SE, Mehta D, Middeldorp CM, Mihailov E, Milaneschi Y, Milani L, Mill J, Mondimore FM, Montgomery GW, Mostafavi S, Mullins N, Nauck M, Ng B, Nivard MG, Nyholt DR, O’Reilly PF, Oskarsson H, Owen MJ, Painter JN, Pedersen CB, Pedersen MG, Peterson RE, Pettersson E, Peyrot WJ, Pistis G, Posthuma D, Purcell SM, Quiroz JA, Qvist P, Rice JP, Riley BP, Rivera M, Saeed Mirza S, Saxena R, Schoevers R, Schulte EC, Shen L, Shi J, Shyn SI, Sigurdsson E, Sinnamon GBC, Smit JH, Smith DJ, Stefansson H, Steinberg S, Stockmeier CA, Streit F, Strohmaier J, Tansey KE, Teismann H, Teumer A, Thompson W, Thomson PA, Thorgeirsson TE, Tian C, Traylor M, Treutlein J, Trubetskoy V, Uitterlinden AG, Umbricht D, Van der Auwera S, van Hemert AM, Viktorin A, Visscher PM, Wang Y, Webb BT, Weinsheimer SM, Wellmann J, Willemsen G, Witt SH, Wu Y, Xi HS, Yang J, Zhang F, eQTLGen; 23andMe, Arolt V, Baune BT, Berger K, Boomsma DI, Cichon S, Dannlowski U, de Geus ECJ, DePaulo JR, Domenici E, Domschke K, Esko T, Grabe HJ, Hamilton SP, Hayward C, Heath AC, Hinds DA, Kendler KS, Kloiber S, Lewis G, Li QS, Lucae S, Madden PFA, Magnusson PK, Martin NG, McIntosh AM, Metspalu A, Mors O, Mortensen PB, Müller-Myhsok B, Nordentoft M, Nöthen MM, O'Donovan MC, Paciga SA, Pedersen NL, Penninx BWJH, Perlis RH, Porteous DJ, Potash JB, Preisig M, Rietschel M, Schaefer C, Schulze TG, Smoller JW, Stefansson K, Tiemeier H, Uher R, Völzke H, Weissman MM, Werge T, Winslow AR, Lewis CM, Levinson DF, Breen G, Børglum AD, Sullivan PF; Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium (2018) Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. Nat Genet 50:668–681. https://doi.org/10.1038/s41588-018-0090-3 CrossRefPubMedPubMedCentral Wray NR, Ripke S, Mattheisen M, Trzaskowski M, Byrne EM, Abdellaoui A, Adams MJ, Agerbo E, Air TM, Andlauer TMF, Bacanu SA, Bækvad-Hansen M, Beekman AFT, Bigdeli TB, Binder EB, Blackwood DRH, Bryois J, Buttenschøn HN, Bybjerg-Grauholm J, Cai N, Castelao E, Christensen JH, Clarke TK, Coleman JIR, Colodro-Conde L, Couvy-Duchesne B, Craddock N, Crawford GE, Crowley CA, Dashti HS, Davies G, Deary IJ, Degenhardt F, Derks EM, Direk N, Dolan CV, Dunn EC, Eley TC, Eriksson N, Escott-Price V, Kiadeh FHF, Finucane HK, Forstner AJ, Frank J, Gaspar HA, Gill M, Giusti-Rodríguez P, Goes FS, Gordon SD, Grove J, Hall LS, Hannon E, Hansen CS, Hansen TF, Herms S, Hickie IB, Hoffmann P, Homuth G, Horn C, Hottenga JJ, Hougaard DM, Hu M, Hyde CL, Ising M, Jansen R, Jin F, Jorgenson E, Knowles JA, Kohane IS, Kraft J, Kretzschmar WW, Krogh J, Kutalik Z, Lane JM, Li Y, Li Y, Lind PA, Liu X, Lu L, MacIntyre DJ, MacKinnon DF, Maier RM, Maier W, Marchini J, Mbarek H, McGrath P, McGuffin P, Medland SE, Mehta D, Middeldorp CM, Mihailov E, Milaneschi Y, Milani L, Mill J, Mondimore FM, Montgomery GW, Mostafavi S, Mullins N, Nauck M, Ng B, Nivard MG, Nyholt DR, O’Reilly PF, Oskarsson H, Owen MJ, Painter JN, Pedersen CB, Pedersen MG, Peterson RE, Pettersson E, Peyrot WJ, Pistis G, Posthuma D, Purcell SM, Quiroz JA, Qvist P, Rice JP, Riley BP, Rivera M, Saeed Mirza S, Saxena R, Schoevers R, Schulte EC, Shen L, Shi J, Shyn SI, Sigurdsson E, Sinnamon GBC, Smit JH, Smith DJ, Stefansson H, Steinberg S, Stockmeier CA, Streit F, Strohmaier J, Tansey KE, Teismann H, Teumer A, Thompson W, Thomson PA, Thorgeirsson TE, Tian C, Traylor M, Treutlein J, Trubetskoy V, Uitterlinden AG, Umbricht D, Van der Auwera S, van Hemert AM, Viktorin A, Visscher PM, Wang Y, Webb BT, Weinsheimer SM, Wellmann J, Willemsen G, Witt SH, Wu Y, Xi HS, Yang J, Zhang F, eQTLGen; 23andMe, Arolt V, Baune BT, Berger K, Boomsma DI, Cichon S, Dannlowski U, de Geus ECJ, DePaulo JR, Domenici E, Domschke K, Esko T, Grabe HJ, Hamilton SP, Hayward C, Heath AC, Hinds DA, Kendler KS, Kloiber S, Lewis G, Li QS, Lucae S, Madden PFA, Magnusson PK, Martin NG, McIntosh AM, Metspalu A, Mors O, Mortensen PB, Müller-Myhsok B, Nordentoft M, Nöthen MM, O'Donovan MC, Paciga SA, Pedersen NL, Penninx BWJH, Perlis RH, Porteous DJ, Potash JB, Preisig M, Rietschel M, Schaefer C, Schulze TG, Smoller JW, Stefansson K, Tiemeier H, Uher R, Völzke H, Weissman MM, Werge T, Winslow AR, Lewis CM, Levinson DF, Breen G, Børglum AD, Sullivan PF; Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium (2018) Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. Nat Genet 50:668–681. https://doi.org/10.1038/s41588-018-0090-3 CrossRefPubMedPubMedCentral

Title: Subclinical inflammation and depressive symptoms in patients with type 1 and type 2 diabetes
Authors: Christian Herder
Norbert Hermanns
Publication date: 01-07-2019
Publisher: Springer Berlin Heidelberg
Keywords: Affective Disorder
Affective Disorder
Cytokines
Type 2 Diabetes
Type 1 Diabetes
Biomarkers
Published in: Seminars in Immunopathology / Issue 4/2019
Print ISSN: 1863-2297
Electronic ISSN: 1863-2300
DOI: https://doi.org/10.1007/s00281-019-00730-x

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Subclinical inflammation and depressive symptoms in patients with type 1 and type 2 diabetes

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2019

Impact of bariatric surgery on type 2 diabetes: contribution of inflammation and gut microbiome?

Transcriptional control of macrophage polarisation in type 2 diabetes

The role of interleukin-6 in glucose homeostasis and lipid metabolism

Role of innate immune cells in metabolism: from physiology to type 2 diabetes

Treatment of type 2 diabetes by targeting interleukin-1: a meta-analysis of 2921 patients

Chronic low-grade inflammation in polycystic ovary syndrome: is there a (patho)-physiological role for interleukin-1?

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page